FDA OK's LEO's Picato for precancerous skin condition
This article was originally published in Scrip
Executive Summary
With the US FDA's blessing of LEO Pharma's topical gel Picato (ingenol mebutate), patients with actinic keratosis, a precancerous condition, which may progress to a nonmelanoma form of skin cancer, known as squamous cell carcinoma, will have access to a once-daily treatment whose use is required for only a few days.